
Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With over two decades of experience in top Indian newsrooms—including Mint, Hindustan Times, the India Today Group, and Zee Media—she has consistently reported on the intersection of public health policy, corporate healthcare, and the pharmaceutical industry. Her journalism spans policy deep dives, industry trends, regulatory shifts, and corporate strategy across India’s thriving hea...

The company is evaluating obesity pipeline but ruled out ‘me-too’ GLP-1 or GIP drugs.

IQVIA and AWS said the collaboration reflects the growing need for cloud-based tools that can support large-scale trial operations and analytical workloads.

AWS is entering a phase where companies will move beyond copilots and assistants to AI agents capable of completing full tasks across IT, operations, security, customer workflows and data-heavy enviro...

AWS also introduced the Trainium 3 chip and new AI-optimised servers designed to handle resource-intensive healthcare workloads such as genomics pipelines, biomarker discovery, molecular-simulation ta...

From adding courses in areas such as AI and sustainability to supporting more than 250 start-ups, IIML has been expanding steadily.

Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, on new launches, India's expanding role in the global innovation pipeline, and more.

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.

Biocon Biologics is expanding its global biosimilars footprint, driven by new launches and market share gains in key therapy areas. The company’s U.S. presence has strengthened through partnerships su...
In an exclusive conversation with Business Today’s Neetu Chandra, Vikrant Shrotriya, Managing Director of Novo Nordisk India, discusses how the company is leading India’s obesity treatment revolution....
Novo Nordisk India has cut prices of its once-weekly obesity drug Wegovy (semaglutide) by 37%, bringing the starting dose down to ₹2,712 per week. The move aims to make evidence-based obesity treatmen...





